Vivodyne is a biotech startup that uses clinically predictive AI to help identify therapeutic targets and predict a patient’s response to a drug using lab-grown human organ tissues. The company was co-founded by Dan Huh, PhD, Associate Professor of Bioengineering at Penn Engineering, and Andrei Georgescu, PhD, who worked in Huh’s lab and is now CEO of Vivodyne. Penn was awarded multiple patents this year on technologies invented by Huh that were foundational to Vivodyne’s conception. According to Georgescu, as Vivodyne continues to grow, the overarching goal is to turn the company into the biological equivalent of a “large-scale data center” that allows scientists access to unprecedented capabilities for researching human disease. Read more here: